지식 홈 인류 보건 지식 All 의견 종이 대중 과학 면접 필터 Therapeutic areas COVID-19 소화기 건강 Apply 홈 인류 보건 지식 Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial 홈 인류 보건 지식 Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2 홈 인류 보건 지식 RBDCOV Talks HIPRA’s participation: In 5 minutes, what is a recombinant protein vaccine? 홈 인류 보건 지식 Humoral immune response against XBB.1.5 and BQ.1.1 SARS-CoV-2 variants of a fourth dose of PHH-1V vaccine in adult subjects 홈 인류 보건 지식 RBDCOV: The project’s origins and future endeavours 홈 인류 보건 지식 Reactogenicity of third and fourth booster doses of HIPRA PHH-1V, a bivalent recombinant protein vaccine against SARS-CoV-2 홈 인류 보건 지식 Humoral immune response against SARS-CoV-2 variants of PHH-1V booster vaccine in subjects previously vaccinated with a mRNA vaccine 홈 인류 보건 지식 One-year humoral response of PHH-1V booster vaccine in subjects previously vaccinated against COVID-19 with a mRNA vaccine 홈 인류 보건 지식 Dr. Àlex Soriano (Hospital Clínic de Barcelona): "Public-private collaboration is essential to achieve significant scientific advances" 더 로드하기
